GlassScriptPhysician profile
Morgan Ritter
NPI 1316529951
$1,602.56
in general payments reported to CMS, 2019-2025
21 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.68 · 2022: $454 · 2023: $541 · 2024: $291 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,111.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $274.11 | 2022-2025 | |
| Novo Nordisk INC | $260.27 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $176.76 | 2023-2025 | |
| Amgen INC. | $173.69 | 2022-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $134.07 | 2022-2025 | Mounjaro, Trulicity, Jardiance |
| Merck Sharp & Dohme LLC | $116.26 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $75.63 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $66.10 | 2022-2023 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $59.23 | 2022-2023 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $40.53 | 2023 | Rexulti |
| Philips North America LLC | $32.95 | 2022 | |
| Phathom Pharmaceuticals, INC. | $32.00 | 2024 | Voquezna |
| Exact Sciences Corporation | $31.47 | 2024 | Cologuard Collection Kit |
| Eisai INC. | $23.64 | 2021 | |
| Lundbeck LLC | $20.51 | 2023 | Rexulti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $19.60 | 2024 | |
| Grifols USA, LLC | $16.31 | 2025 | Prolastin-C Liquid |
| Cranial Technologies, INC | $13.04 | 2021 | |
| Sumitomo Pharma America, INC. | $12.94 | 2023 | Gemtesa |
| Glaxosmithkline, LLC. | $11.75 | 2022 | |
| Urovant Sciences INC | $11.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Ritter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.